摘要
本文分析了国内22城市(地区)样本医院用药数据,发现,近三年样本医院购入药品总金额增幅继续保持在12%左右,整个医院市场趋于平稳;抗感染药物目前已进入常态化管理,已从负增长的困境中走出,该大类药物在样本医院中所占份额不容忽视;供应医院领先厂商中进口、合资企业较本土企业稍占优势,提示,二三级医院对药品的临床使用效果或药品的来源及质量相当重视。
In this review, a comprehensive analysis is made based on the drug-use data of domestic 22 area sample hospitals. The conclusion shows that the gross amount of drug purchase in sample hospitals maintains a growth rate of about 12% in recent 3 years. The whole hospital drug-use market is stable. The anti-infective drug has been turned into a normal management and has come out from the negative growth dilemma. According to the sales of leading manufacturing companies in this market, Multinational corporations and joint venture enterprises take a little advantage compared with the local ones. It shows that the clinical efficacy and drug quality are very important issues for the drug sources in hospitals.
出处
《世界临床药物》
CAS
2014年第11期I0018-I0023,共6页
World Clinical Drug
关键词
医院用药
政策影响
领先品种
领先厂商
hospital drug-use
policy influence
leading product
leading company
